Inflammation: a swell cure

Treatments for chronic inflammatory diseases are one step closer with University of Queensland researchers’ discovery of a way to stop inflammation.

A study, led by Associate Professor Kate Schroder and Dr Rebecca Coll from UQ’s Institute for Molecular Bioscience and Professor Avril Robertson from UQ’s School of Chemistry and Molecular Biosciences, will inform the design of new drugs to stop the formation of a protein complex, the inflammasome, which drives inflammation.

Dr Coll says the inflammasome is important in protecting our bodies from infection, but is also a key driver of unhealthy inflammation.

“Inflammation helps our bodies heal following infection, but when the inflammasome is not switched off, inflammation becomes damaging,” she said.

“Uncontrolled inflammation results in chronic diseases, such as Parkinson’s disease, Alzheimer’s disease and respiratory diseases such as asthma.”

Professor Schroder says the team’s discovery gives new insight into how to stop inflammation at the molecular level.

“We previously identified a small molecule, MCC950, that inhibits the inflammasome and blocks inflammation in disease but, until now, we didn’t understand how it worked,” she said.

“We discovered that MCC950 binds directly to the inflammasome and inactivates it, turning off inflammation.

“Now that we understand how a small molecule can inhibit the inflammasome, we’re very excited about the potential of inflammasome inhibitors as anti-inflammatory drugs.

Professor Robertson said: “UQ start-up Inflazome Ltd, which is developing targeted therapies for inflammatory diseases, has announced its plans to commence clinical trials of their inflammasome inhibitors in 2019, and other companies are competing in this space.

“We’re keen to see results of these trials and hope that our discovery can lead to the efficient design of new molecules as anti-inflammatory drugs of the future.”

The research was published in the scientific journal <itals>Nature Chemical Biology<itals> and supported by the National Health and Medical Research Council of Australia and the Australian Research Council.

 

Must Read

New regional roadmaps for prioritising antimicrobial resistance

0
A new publication by the International Pharmaceutical Federation (FIP) identifies priority actions pharmacists should take to minimise antimicrobial resistance (AMR). The publication presents six...